Chengdu's HitGen to Collaborate with Global Blood Therapeutics
Author:Yestar      Time:2016-01-12
HitGen Ltd, a Chengdu CRO specializing in drug discovery, formed a research collaboration with Global Blood Therapeutics of the US, a clinical-stage biopharma focused on therapeutics for blood-based disorders. HitGen will provide biology, chemistry, and screening on an undisclosed novel GBT target. GBT's lead molecule is a clinical-stage drug candidate that treats the underlying mechanism of sickle cell disease, which was recently granted Orphan Drug designation in the US.
0

Copyright © 2017 Yestar Healthcare Holdings Company Limited     Powered By : Yestarcorp    沪ICP备10207132号-5

  沪公网安备 31011202004160号